Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
ESMO Open|August 29, 2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket studyV Boni, B Pistilli, I Braña, et al.
ESMO Open|November 29, 2024
Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohortF Giugliano, A Bertaut, J Blanc, et al.
Leukemia Research|January 30, 2017
Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic diseaseM Annereau, C Willekens, L El Halabi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancerL Cabel, F Berger, T Bachelot, et al.
ESMO Open|June 20, 2022
Factors associated with enrolment in clinical trials among women with early-stage breast cancerD Presti, J Havas, D Soldato, et al.
ESMO Open|June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)C Parisi, M Banini, F Mantuano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 7, 2018
5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French studyA Ploquin, B Pistilli, E Tresch, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patientsE Jacquet, A Lardy-Cléaud, B Pistilli, et al.
ESMO Open|February 13, 2024
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomesM A Franzoi, M Aupomerol, J Havas, et al.
Pageof 3